About this document
SGLT-2 Inhibitors in Diabetic Kidney Disease by Celia Fidalgo is a document available to read on EtoBox.
This review discusses the role and mechanisms of SGLT-2 inhibitors in treating diabetic kidney disease (DKD), highlighting their significant cardiorenal protective effects, especially in patients with stage G4 DKD. Recent studies have shown that these inhibitors can improve renal function and delay disease progression, challenging previous beliefs about their efficacy at lower eGFR levels. The paper emphasizes the need for further research to fully understand the mechanisms behind SGLT-2 inhibitors
- Author
- Celia Fidalgo
- Language
- EN